Cargando…

PI3K Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Current Status and Future Perspectives

SIMPLE SUMMARY: The development of small agents targeting the B-cell receptor (BCR) pathway revolutionized the treatment of chronic lymphocytic leukemia (CLL). BCR-dependent leukemic cell proliferation is governed by phosphoinositide 3-kinase (PI3K) signaling. The selective PI3Kδ inhibitor idelalisi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hus, Iwona, Puła, Bartosz, Robak, Tadeusz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945984/ https://www.ncbi.nlm.nih.gov/pubmed/35326722 http://dx.doi.org/10.3390/cancers14061571

Ejemplares similares

The Role of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions
por: Robak, Tadeusz, et al.
Publicado: (2022)

Editorial: Novel targeted drugs for indolent lymphoid malignancies
por: Robak, Tadeusz, et al.
Publicado: (2023)

Atypical Chronic Lymphocytic Leukemia—The Current Status
por: Robak, Tadeusz, et al.
Publicado: (2023)

Current concepts in diagnosis and treatment of chronic lymphocytic leukemia
por: Hus, Iwona, et al.
Publicado: (2015)

Bruton’s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives
por: Robak, Ewa, et al.
Publicado: (2022)

Application of New Drugs in Chronic Lymphocytic Leukemia
por: Robak, Tadeusz
Publicado: (2010)

Cardiac Involvement in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
por: Robak, Tadeusz, et al.
Publicado: (2022)

Circulating proangiogenic cytokines and angiogenesis inhibitor endostatin in untreated patients with chronic lymphocytic leukemia.
por: Gora-Tybor, Joanna, et al.
Publicado: (2003)

Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia
por: Puła, Bartosz, et al.
Publicado: (2019)

Zanubrutinib for the treatment of lymphoid malignancies: Current status and future directions
por: Wolska-Washer, Anna, et al.
Publicado: (2023)

Secondary malignancies and survival of FCR‐treated patients with chronic lymphocytic leukemia in Central Europe
por: Kósa, Fruzsina, et al.
Publicado: (2022)

Leukemia Cutis—The Current View on Pathogenesis, Diagnosis, and Treatment
por: Robak, Ewa, et al.
Publicado: (2023)

Lights and Shade of Next-Generation Pi3k Inhibitors in Chronic Lymphocytic Leukemia
por: Visentin, Andrea, et al.
Publicado: (2020)

TLR2 Expression on Leukemic B Cells from Patients with Chronic Lymphocytic Leukemia
por: Szymańska, Agata, et al.
Publicado: (2018)

Personalized therapy tests for the monitoring of chronic lymphocytic leukemia development
por: Rogalińska, Małgorzata, et al.
Publicado: (2017)

Mean Platelet Volume Has Prognostic Value in Chronic Lymphocytic Leukemia
por: Masternak, Marta, et al.
Publicado: (2020)

The Significance of mRNA in the Biology of Multiple Myeloma and Its Clinical Implications
por: Puła, Anna, et al.
Publicado: (2021)

Current and future treatment strategies in chronic lymphocytic leukemia
por: Patel, Krish, et al.
Publicado: (2021)

PI3K inhibitors in chronic lymphocytic leukemia: where do we go from here?
por: Skånland, Sigrid S., et al.
Publicado: (2022)

Clinical efficacy and tolerability of venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia—a real-world analysis of the Polish Adult Leukemia Study Group
por: Soboń, Anita, et al.
Publicado: (2023)

Intracellular IL-4 and IFN-γ expression in iNKT cells from patients with chronic lymphocytic leukemia
por: Bojarska-Junak, Agnieszka, et al.
Publicado: (2018)

Current Status of Older and New Purine Nucleoside Analogues in the Treatment of Lymphoproliferative Diseases
por: Robak, Tadeusz, et al.
Publicado: (2009)

Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy
por: Sirico, Marianna, et al.
Publicado: (2023)

Outcome of SARS-CoV-2-Infected Polish Patients with Chronic Lymphocytic Leukemia
por: Puła, Bartosz, et al.
Publicado: (2022)

A T Cell Inflammatory Phenotype is Associated with Autoimmune Toxicity of the PI3K Inhibitor Duvelisib in Chronic Lymphocytic Leukemia
por: Gadi, Deepti, et al.
Publicado: (2022)

Intragenic Variations in BTLA Gene Influence mRNA Expression of BTLA Gene in Chronic Lymphocytic Leukemia Patients and Confer Susceptibility to Chronic Lymphocytic Leukemia
por: Karabon, Lidia, et al.
Publicado: (2016)

Hedgehog/GLI and PI3K signaling in the initiation and maintenance of chronic lymphocytic leukemia
por: Kern, D, et al.
Publicado: (2015)

PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL)
por: Okkenhaug, Klaus, et al.
Publicado: (2015)

A clinical perspective on plasma cell leukemia; current status and future directions
por: Tuazon, Sherilyn A., et al.
Publicado: (2021)

Oral PI3K-δ,γ Inhibitor for the Management of People with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Narrative Review on Duvelisib
por: Shah, Ankit, et al.
Publicado: (2021)

Skin changes in hairy cell leukemia
por: Robak, Ewa, et al.
Publicado: (2020)

Measurable residual disease in hairy cell leukemia: Technical considerations and clinical significance
por: Robak, Tadeusz, et al.
Publicado: (2022)

Time-Restricted Eating and Metabolic Syndrome: Current Status and Future Perspectives
por: Świątkiewicz, Iwona, et al.
Publicado: (2021)

Th17/IL-17A Might Play a Protective Role in Chronic Lymphocytic Leukemia Immunity
por: Hus, Iwona, et al.
Publicado: (2013)

Inhibitors Targeting YAP in Gastric Cancer: Current Status and Future Perspectives
por: Yong, Jiaxin, et al.
Publicado: (2021)

Targeted PI3K/AKT-hyperactivation induces cell death in chronic lymphocytic leukemia
por: Ecker, Veronika, et al.
Publicado: (2021)

Antibody and Plasmablast Response to 13-Valent Pneumococcal Conjugate Vaccine in Chronic Lymphocytic Leukemia Patients – Preliminary Report
por: Pasiarski, Marcin, et al.
Publicado: (2014)

PI3K Inhibitors in Advanced Breast Cancer: The Past, The Present, New Challenges and Future Perspectives
por: Fuso, Paola, et al.
Publicado: (2022)

The present and future of PI3K inhibitors for cancer therapy
por: Castel, Pau, et al.
Publicado: (2021)

Endocan in Acute Leukemia: Current Knowledge and Future Perspectives
por: Reikvam, Håkon, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8174gd1ehjr0a67r11apgu7lge